Port Houston Celebrates Record-Breaking Performance, Major Milestones
Port Commission’s Meeting Spotlights Leadership, Community and Employee RecognitionHOUSTON--(BUSINESS WIRE)--On Wednesday, February…
MET DEVELOPMENT (MAIRE), ENI AND IREN START THE AUTHORIZATION PROCESS FOR A CIRCULAR METHANOL AND HYDROGEN PLANT IN ITALY BASED ON NEXTCHEM’S NX CIRCULARTM TECHNOLOGY
NEXTCHEM's NX CircularTM waste-to-energy gasification technology allows Eni's Sannazzaro de' Burgondi refinery…
SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS FIRST-IN-HUMAN STUDY
Primary safety endpoint met - No serious adverse events reported over 3-monthsRobust…
Grace Therapeutics Announces Third Fiscal Quarter 2025Financial Results, Provides Business Update
Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical…
When the world of food met at IIHM Kolkata, for a better world
50 Young Chef Olympians wore their national dress, cooked their national dish…
Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
Primary endpoint of DFS met at first prespecified interim analysis, showing a…
HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE…
Communiqu of the 13th Olympic Summit
07 December 2024 - At the invitation of the International Olympic Committee…
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS)…
HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at CurrentTerms
November 28, 2024 05:30 ET | Source: HUTCHMED (China) Limited HONG KONG…